India
· Delayed Price · Currency is INR | Market Cap | 50.51B |
| Revenue (ttm) | 6.87B |
| Net Income (ttm) | 915.10M |
| Shares Out | n/a |
| EPS (ttm) | 17.08 |
| PE Ratio | 55.20 |
| Forward PE | 40.52 |
| Dividend | 18.00 (1.81%) |
| Ex-Dividend Date | Aug 16, 2024 |
| Volume | 203,448 |
| Average Volume | 89,328 |
| Open | 983.00 |
| Previous Close | 996.70 |
| Day's Range | 874.10 - 995.50 |
| 52-Week Range | 572.00 - 1,073.20 |
| Beta | 0.46 |
| RSI | 49.32 |
| Earnings Date | Apr 23, 2025 |
About Thyrocare Technologies
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The company conducts various medical diagnostic tests and profiles of tests that focuses on early detection and management of disorders and diseases, including thyroid, growth, metabolism, auto-immunity, diabetes, anaemia, cardiovascular, infertility, and various infectious diseases. Its profiles of tests include profiles of tests adm... [Read more]
Financial Performance
In 2024, Thyrocare Technologies's revenue was 6.87 billion, an increase of 20.19% compared to the previous year's 5.72 billion. Earnings were 915.10 million, an increase of 29.32%.
Financial StatementsNews
Thyrocare Technologies Q4 results: Revenue up 21% YoY to Rs 187.2 crore, PAT jumps 88% YoY; Board recommends Rs 21 dividend per share
Thyrocare Technologies Limited has recommended a final dividend of ₹21 per equity share for FY25, subject to approval by shareholders at the ensuing AGM. This announcement comes as the company posts a...
Thyrocare Technologies Q3 FY25 Results: Revenue jumps 23.2% YoY to Rs 165.9 crore, Net Profit surges 24% YoY
Thyrocare Technologies has delivered a strong performance in the third quarter of FY25, reporting notable growth across key financial metrics. The company’s net profit surged by 24% year-on-year (YoY)...